A Study of Ribavirin to Treat M4 and M5 Acute Myelocytic Leukemia
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if ribavirin (a drug commonly used to treat
hepatitis C) also has activity in the treatment of patients with refractory or relapsed acute
myeloid leukemia (AML) of the M4 and M5 subtype.